Panel Business of Biotech track
Capital, Creativity, and Optionality: The New Anatomy of Life Sciences Transactions
Tue, Nov 10, 2026 · 4:00–4:45 PM CET Business of Biotech Stage, Koelnmesse
About this session
As biopharma dealmaking accelerates—driven by record licensing values, a $200 billion patent cliff, and a selective capital markets environment—companies and investors are turning to increasingly creative transactional structures to unlock value and maintain strategic optionality. This panel brings together three of Ropes & Gray's leading life sciences transactional partners for a forward-looking discussion on the trends reshaping how biotech companies capitalize their programs and bring assets to market.
Speakers
-
Partner · Ropes & Gray
Panelist
-
Partner · Ropes & Gray
Panelist
-
Associate Director & Business Development Lead · Astellas Pharma
Panelist
-
Advisor (EU & UK) · Healthcare Royalty Partners
Panelist
-
VP, Head of Immunology, Metabolism, ID Partnering · Regeneron
Panelist